checkAd

     765  0 Kommentare Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform - Seite 4

    Notice Regarding Forward-Looking Statements

    This press release contains forward-looking statements that involve substantial uncertainties and risks. These forward-looking statements are based upon our current expectations, estimates and projections and reflect our beliefs and assumptions based upon information available to us at the date of this release. We caution readers that forward-looking statements are predictions based on our current expectations about future events. These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties and assumptions that are difficult to predict. Our actual results, performance or achievements could differ materially from those expressed or implied by the forward-looking statements as a result of a number of factors, including, but not limited to, the expectations of management regarding the success of the joint ventures and expanding our market penetration in the CMDO field in Europe and Asia; the successful integration of our clinical and CDMO strategy; the development of our regeneration technology as therapeutic treatment for diabetes which could, if successful, be a cure for Type 1 Diabetes; our limited financial resources and our ability to raise the working capital needed to fund the commitments of our CDMO business, various joint ventures, development projects and business generally; our technology not working as well as expected; our ability to retain key employees; our ability to satisfy the rigorous regulatory requirements for new medical procedures; our competitors developing better or cheaper alternatives to our products and the risks and uncertainties discussed under the heading "RISK FACTORS" in Item 1 of our Annual Report on Form 10-K for the fiscal year ended November 30, 2015, and in our other filings with the Securities and Exchange Commission. We undertake no obligation to revise or update any forward-looking statement for any reason.

    Contact:
    David Waldman
    Crescendo Communications, LLC
    (212) 671-1020 x301
    orgs@crescendo-ir.com

    Seite 4 von 4





    Verfasst von Marketwired
    Servier Appoints MaSTherCell for the Development of its CAR-T Cell Therapy Manufacturing Platform - Seite 4 GERMANTOWN, MD--(Marketwired - Jan 20, 2017) -   Orgenesis Inc. (OTCQB: ORGS), a fully-integrated cell therapy and contract development and manufacturing company, announced that its wholly-owned subsidiary, MaSTherCell S.A., specializing in the …